Y Mabs Therapeutics Inc (YMAB) Return on Equity ROE from the second quarter 2025 to second quarter 2024 and annually, average high and low, overall ranking from Jun 30 2025 to Jun 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Y mabs Therapeutics inc   (NASDAQ: YMAB)

Y Mabs Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Y Mabs Therapeutics Inc in the second quarter 2025?
Y Mabs Therapeutics Inc recorded a cumulative net loss of $-22 million during 12 months ending in the second quarter 2025, resulting in a negative return on equity (ROE) of -24.6%.

Within the Major Pharmaceutical Preparations industry 106 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2025 from 2642 to 3019.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter
Y / Y Equity Change -8.23 % -9.81 % -8.89 % -7.71 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -22 -28 -30 -24 -25
Return On Equity (TTM) -24.6 % -30.59 % -31.31 % -24.61 % -24.88 %
YMAB's Total Ranking # 3019 # 2642 # 2819 # 1995 # 2075
Equity (TTM) in Millions 87 89 92 92 95
Seq. Equity Change -2.2 % -2.77 % -0.46 % -3.05 % -3.88 %
Seq. Net Income Change - - - - -

Back to YMAB Management Effectiveness >> YMAB's 5 Years Annual ROE >> Compare YMAB ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 107
Sector # 297
Overall # 3019

Return On Equity Statistics
High Average Low
-16.67 %
-41.56 %
-92.65 %
(Sep 30 2019)   (Sep 30 2022)





YMAB Annual Return On Equity (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020
Total Equity in Millions 92 101 109 180 106
Y / Y Equity Change -8.89 % -7.54 % -39.36 % 70.17 % -46.79 %
Net Income in Millions -30 -21 -96 -55 -119
Y / Y Net Income Change - - - - -
Return On Equity -32.24 % -21.22 % -87.5 % -30.69 % -112.76 %

Back to YMAB Management Effectiveness >> YMAB's 5 Years Annual ROE >> Compare YMAB ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
YMAB's' Return on Equity at Yahoo Finance
YMAB's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for YMAB's Competitors
Subscribers only: Roe for Y Mabs Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for YMAB's Customers




Companies with similar Return On Equity at Jun 30 2025, within Healthcare Sector ROE

Date modified: 2026-08-29T17:41:26+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.